Smith & Nephew releases full-year report, appoints new CEO

British medtech company Smith & Nephew is on the rise on the London stock exchange, following a full-year report and announcement that a Siemens Healthineers manager has been brought in as CEO replacement.

Smith & Nephew competes with Danish firm Coloplast on the wound care market | Photo: Stine Bidstrup/JP

On Tuesday, British medtech company Smith & Nephew, a competitor of Coloplast within wound care, has announced a CEO replacement in connection with the release of its full-year financial figures. The double news has been rewarded well on the London stock exchange, sending the company up by 2.1 percent to GBP 12.04.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs